CM-4307

DB15414InvestigationalSmall molecule

CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

Mechanism: Pharmacologically active on RAF proto-oncogene serine/threonine-protein kinase, Receptor-type tyrosine-protein kinase FLT3, and Mast/stem cell growth factor receptor Kit
Curator reviewed
Formula / weight: C₂₁H₁₆ClF₃N₄O₃ · 467.85 g/mol (avg)
Also known as: DONAFENIB
Code names: CM-4307

Resolves to

Compound

Structure

InChIKeyMLDQJTXFUGDVEO-FIBGUPNXSA-NSMILES[2H]C([2H])([2H])NC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1

Targets

What you can answer from here — as of July 08, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

57Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with CM-4307, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.